Skip to main content

Cellzome Snags More Than $3.1M in Grants for EU-, UK-Sponsored Research Initiatives

Premium

Proteomics firm Cellzome said this week it has won more than €2.3 million ($3.1 million) in grants funding its participation in three separate research projects.

The funding supports Cellzome’s work in: Blueprint, an EU-funded effort to analyze the epigenome of the hematopoietic system; Orchid, an EU-funded project in which Cellzome will work under the direction of drugmaker GlaxoSmithKline to identify new drug targets in tuberculosis; and a stem cell characterization project the company has undertaken in collaboration with Pfizer, the University of Sheffield, and the stem cell firm Plasticell (see story this issue).

The company will receive €1.2 million for its work on the Blueprint project, €1.1 million for its stem cell research, and an undisclosed amount for its participation in the Orchid project, which, according to Cellzome chief scientific officer David Simmons, will be centered at GSK’s “Open Lab” in Tres Cantos, Spain.

Cellzome will be using its Episphere and Kinobeads chemoproteomics platforms in these projects, as well as mass spec-based proteome-wide screening methods.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.